Clinical Trial Update: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial of lenvatinib in iodine-refractory differentiated thyroid cancer completed with posted results in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer
• Thyroid Cancer

Drugs mentioned

• Lenvatinib (lenvatinib)

Snippet

Sponsor: Eisai Inc. | Conditions: Thyroid Cancer | Phase 3 | Status: COMPLETED | Results posted: 2016-12-12